NAFLDsym v2B is a mechanistic, mathematical computational model of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), and metabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis (NASH). This platform is designed to predict the efficacy of various treatment modalities developed for these liver diseases. It has been widely utilized by several large pharmaceutical companies to support and optimize clinical trial design and to inform critical clinical development decision-making. The software addresses the significant challenge of heterogeneity within MASLD/MASH, providing a robust tool for researchers. NAFLDsym v2B is available for in-house use through corporate software licenses, or via consulting arrangements with the company's experts. As downloadable computer software, it conducts simulations of compounds, such as drugs or chemicals, to evaluate and model their effects on liver disease pathophysiology.

Features & Benefits

• Comprehensive Disease Pathophysiology Modeling
  • NAFLDsym v2B incorporates the mechanistic underpinnings and primary components of MASLD and MASH pathophysiology, allowing for detailed simulation of disease progression and response.
  • Steatosis
  • Regulation of liver triglyceride and fatty acids
  • Lipotoxicity
  • Fibrosis
  • Inflammation
  • Liver injury and proliferation
  • Hepatocellular bioenergetics
  • Dynamic body weight and its effects on lipids
  • Biomarkers (e.g., ALT, AST, cytokeratin cleaved K18, NAS, MRI, MRE, fibrosis score)
• Drug Efficacy Prediction & Compound Simulation
  • The platform predicts the efficacy of various treatment modalities and conducts simulations of compounds (drugs or chemicals) to evaluate and model their effects on liver disease.
• Clinical Trial Optimization & Decision Support
  • Utilized by pharmaceutical companies to support clinical trial design optimization and to inform critical clinical development decision-making processes.